SEAMLESS Trademark

Trademark Overview


On Thursday, December 14, 2023, a trademark application was filed for SEAMLESS with the United States Patent and Trademark Office. The USPTO has given the SEAMLESS trademark a serial number of 79402309. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Saturday, September 7, 2024. This trademark is owned by Seamless Therapeutics GmbH. The SEAMLESS trademark is filed in the Chemical Products, Pharmaceutical Products, Medical Instrument Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:

Pharmaceutical and biological preparations or active substances for the treatment of diseases; medical, pharmaceutical and biopharmaceutical preparations and substances for the treatment of diseases; pharmaceutical goods and preparations, namely gene transfer, regulation, modulation and delivery medications for the treatment of genetic diseases and disorders; products, agents, for medical purposes, for veterinary purposes; genome editable enzymes; dna recombinant enzymes; dna editable enzymes, especially, recombinases and integrases; genome editable enzymes for the treatment of diseases; dna recombinant enzymes for the treatment of diseases; dna editable enzymes, in particular recombinases and integrases, for the treatment of diseases.

Chemicals for use in industry and science; biological preparations, biological reagents, for use in industry and science.

Medical services; medical analysis relating to the treatment of persons; assay services, for treatment purposes; medical services and medical services, in relation to the following fields: genome editing; genetic counseling; therapy services; services for the preparation of medical reports; providing personalised healthcare and medical information; providing therapy recommendations; providing of information and counselling services, in relation to the following fields: medical services, health care services; therapy consultancy, in relation to the following fields: genome editing; counselling relating to recombinases and integrases for the treatment of diseases.

Medical apparatus and instruments; laboratory apparatus for medical diagnostic purposes.

Scientific and technological services and research, especially creation and application of bioinformatic algorithms and models; science and technology services, scientific and technological research, scientific development services, technological development, relating to the following sectors: gene, genome and cell editing, modulation, modification, engineering, regulation, repair and therapy for the development of pharmaceutical and biological preparations or medications for humans and diagnostic goods and services; consultancy services relating to development of pharmaceutical and biological preparations or medications for humans in the field of gene, genome and cell editing, modulation, modification, engineering, regulation, repair and therapy; genome engineering services; scientific research relating to genetics, scientific research, relating to the following sectors: genome editing; analytical laboratory services; medical laboratory services; scientific laboratory services; resear...
seamless

General Information


Serial Number79402309
Word MarkSEAMLESS
Filing DateThursday, December 14, 2023
Status641 - NON-FINAL ACTION - MAILED
Status DateSaturday, September 7, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical and biological preparations or active substances for the treatment of diseases; medical, pharmaceutical and biopharmaceutical preparations and substances for the treatment of diseases; pharmaceutical goods and preparations, namely gene transfer, regulation, modulation and delivery medications for the treatment of genetic diseases and disorders; products, agents, for medical purposes, for veterinary purposes; genome editable enzymes; dna recombinant enzymes; dna editable enzymes, especially, recombinases and integrases; genome editable enzymes for the treatment of diseases; dna recombinant enzymes for the treatment of diseases; dna editable enzymes, in particular recombinases and integrases, for the treatment of diseases.
Goods and ServicesChemicals for use in industry and science; biological preparations, biological reagents, for use in industry and science.
Goods and ServicesMedical services; medical analysis relating to the treatment of persons; assay services, for treatment purposes; medical services and medical services, in relation to the following fields: genome editing; genetic counseling; therapy services; services for the preparation of medical reports; providing personalised healthcare and medical information; providing therapy recommendations; providing of information and counselling services, in relation to the following fields: medical services, health care services; therapy consultancy, in relation to the following fields: genome editing; counselling relating to recombinases and integrases for the treatment of diseases.
Goods and ServicesMedical apparatus and instruments; laboratory apparatus for medical diagnostic purposes.
Goods and ServicesScientific and technological services and research, especially creation and application of bioinformatic algorithms and models; science and technology services, scientific and technological research, scientific development services, technological development, relating to the following sectors: gene, genome and cell editing, modulation, modification, engineering, regulation, repair and therapy for the development of pharmaceutical and biological preparations or medications for humans and diagnostic goods and services; consultancy services relating to development of pharmaceutical and biological preparations or medications for humans in the field of gene, genome and cell editing, modulation, modification, engineering, regulation, repair and therapy; genome engineering services; scientific research relating to genetics, scientific research, relating to the following sectors: genome editing; analytical laboratory services; medical laboratory services; scientific laboratory services; research laboratories; scientific research and development; development of pharmaceutical preparations and medicines; pharmaceutical products development; bioinformatic research for identification of target sequences for genome editing in a cell's DNA; bioinformatic research for identification of target sequences for genome editing in a cell's DNA by genome editable enzymes, DNA recombinant enzymes, dna editable enzymes, in particular recombinases and integrases; bioinformatic or computational analysis to identify target sequences in a cell's DNA; screening processes for the identification of genome editable enzymes, DNA recombinant enzymes, dna editable enzymes, in particular recombinases and integrases; research and development for the pharmaceutical industry; technological consultancy, relating to the following sectors: treatment of diseases by means of genome editable enzymes, dna recombinant enzymes, dna editable enzymes, in particular recombinases and integrases.

Classification Information


International Class001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
US Class Codes001, 005, 006, 010, 026, 046
Class Status Code6 - Active
Class Status DateThursday, August 15, 2024
Primary Code001
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, August 15, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials.
US Class Codes026, 039, 044
Class Status Code6 - Active
Class Status DateThursday, August 15, 2024
Primary Code010
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, August 15, 2024
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, August 15, 2024
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameSeamless Therapeutics GmbH
Party Type10 - Original Applicant
Legal Entity Type98 - Unknown
AddressDE

Trademark Events


Event DateEvent Description
Thursday, August 15, 2024SN ASSIGNED FOR SECT 66A APPL FROM IB
Wednesday, August 21, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, August 21, 2024APPLICATION FILING RECEIPT MAILED
Thursday, August 22, 2024ASSIGNED TO EXAMINER
Saturday, September 7, 2024NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Saturday, September 7, 2024REFUSAL PROCESSED BY MPU
Tuesday, September 3, 2024NON-FINAL ACTION WRITTEN
Wednesday, September 4, 2024NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW